Arcus Biosciences (RCUS) Stock Forecast & Price Target

Compare

482 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RCUS Analyst Ratings

Strong Buy

8 Buy

1 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Arcus

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RCUS Stock 12 Month Forecast

Average Price Target

$25.29

▲(170.48%Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Arcus Biosciences in the last 3 months. The average price target is $25.29 with a high forecast of $46.00 and a low forecast of $12.00. The average price target represents a 170.48% change from the last price of $9.35.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","47":"$47","16.25":"$16.25","26.5":"$26.5","36.75":"$36.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":46,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$46.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,16.25,26.5,36.75,47],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.22,12.04923076923077,14.87846153846154,17.70769230769231,20.536923076923078,23.366153846153846,26.19538461538462,29.024615384615387,31.853846153846156,34.683076923076925,37.512307692307694,40.34153846153846,43.17076923076923,{"y":46,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.22,10.456153846153846,11.692307692307693,12.928461538461539,14.164615384615384,15.400769230769232,16.636923076923075,17.873076923076923,19.10923076923077,20.345384615384617,21.581538461538464,22.817692307692308,24.053846153846152,{"y":25.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.22,9.433846153846154,9.647692307692308,9.861538461538462,10.075384615384616,10.28923076923077,10.503076923076923,10.716923076923077,10.930769230769231,11.144615384615385,11.358461538461539,11.572307692307692,11.786153846153846,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.5,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.07,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.3,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.71,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.12,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.42,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.89,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.71,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$46.00

Average Price Target$25.29

Lowest Price Target$12.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

-3.74%

Downside

Reiterated

06/12/25

Arcus Biosciences receives a score of 51, primarily due to its financial challenges and valuation concerns. While strong cash reserves and promising clinical developments offer potential upside, the company's ongoing profitability issues and pipeline risks limit its attractiveness. Technical indicators provide mixed signals, requiring cautious optimism from investors.

Eva Fortea VerdejoWells Fargo

Wells Fargo

$40→$26

Buy

178.07%

Upside

Reiterated

06/03/25

Wells Fargo Sticks to Its Buy Rating for Arcus Biosciences (RCUS)

Emily BodnarH.C. Wainwright

H.C. Wainwright

$24

Buy

156.68%

Upside

Reiterated

06/03/25

Promising Efficacy and Safety of Arcus Biosciences' Combination Therapy Reinforces Buy Rating

Peter LawsonBarclays

Barclays

$14

Buy

49.73%

Upside

Reiterated

06/03/25

Barclays Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)

Jason ZemanskyBank of America Securities

Bank of America Securities

$12

Hold

28.34%

Upside

Reiterated

06/02/25

Arcus Biosciences: Promising Results Amidst Uncertainty and Safety Concerns

Asthika GoonewardeneTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/02/25

Arcus Biosciences (RCUS) Gets a Buy from Truist Financial

Daina GrayboschLeerink Partners

Leerink Partners

$46

Buy

391.98%

Upside

Reiterated

06/02/25

Analysts Offer Insights on Healthcare Companies: Exact Sciences (NASDAQ: EXAS) and Arcus Biosciences (NYSE: RCUS)

Terence FlynnMorgan Stanley

Morgan Stanley

$24→$22

Buy

135.29%

Upside

Reiterated

05/09/25

Arcus Biosciences (RCUS) PT Lowered to $22 at Morgan StanleyMorgan Stanley analyst Terence Flynn lowered the price target on Arcus Biosciences (NYSE: RCUS) to $22.00 (from $24.00) while maintaining a Overweight rating.

Robert DriscollWedbush

Wedbush

$33

Buy

252.94%

Upside

Initiated

05/07/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Umer RaffatEvercore ISI

Evercore ISI

―

Buy

―

Reiterated

05/07/25

Analysts Offer Insights on Healthcare Companies: Evolus (NASDAQ: EOLS) and Arcus Biosciences (NYSE: RCUS)

Yigal NochomovitzCiti

Citi

$46

Buy

391.98%

Upside

Reiterated

03/13/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcus Biosciences (NYSE: RCUS), aTyr Pharma (NASDAQ: ATYR) and Lyra Therapeutics (NASDAQ: LYRA)

Salim SyedMizuho Securities

Mizuho Securities

―

Buy

―

Reiterated

02/18/25

Unknown AnalystCantor Fitzgerald

Not Ranked

Cantor Fitzgerald

―

Buy

―

Reiterated

07/05/24

Cantor Fitzgerald reiterates Overweight Rating on Arcus Biosciences (RCUS)Cantor Fitzgerald analyst Alethia Young reiterated an Overweight rating on Arcus Biosciences (NYSE: RCUS).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

-3.74%

Downside

Reiterated

06/12/25

Eva Fortea VerdejoWells Fargo

Wells Fargo

$40→$26

Buy

178.07%

Upside

Reiterated

06/03/25

Wells Fargo Sticks to Its Buy Rating for Arcus Biosciences (RCUS)

Emily BodnarH.C. Wainwright

H.C. Wainwright

$24

Buy

156.68%

Upside

Reiterated

06/03/25

Promising Efficacy and Safety of Arcus Biosciences' Combination Therapy Reinforces Buy Rating

Peter LawsonBarclays

Barclays

$14

Buy

49.73%

Upside

Reiterated

06/03/25

Barclays Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)

Jason ZemanskyBank of America Securities

Bank of America Securities

$12

Hold

28.34%

Upside

Reiterated

06/02/25

Arcus Biosciences: Promising Results Amidst Uncertainty and Safety Concerns

Asthika GoonewardeneTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/02/25

Arcus Biosciences (RCUS) Gets a Buy from Truist Financial

Daina GrayboschLeerink Partners

Leerink Partners

$46

Buy

391.98%

Upside

Reiterated

06/02/25

Analysts Offer Insights on Healthcare Companies: Exact Sciences (NASDAQ: EXAS) and Arcus Biosciences (NYSE: RCUS)

Terence FlynnMorgan Stanley

Morgan Stanley

$24→$22

Buy

135.29%

Upside

Reiterated

05/09/25

Robert DriscollWedbush

Wedbush

$33

Buy

252.94%

Upside

Initiated

05/07/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Umer RaffatEvercore ISI

Evercore ISI

―

Buy

―

Reiterated

05/07/25

Analysts Offer Insights on Healthcare Companies: Evolus (NASDAQ: EOLS) and Arcus Biosciences (NYSE: RCUS)

Yigal NochomovitzCiti

Citi

$46

Buy

391.98%

Upside

Reiterated

03/13/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcus Biosciences (NYSE: RCUS), aTyr Pharma (NASDAQ: ATYR) and Lyra Therapeutics (NASDAQ: LYRA)

Salim SyedMizuho Securities

Mizuho Securities

―

Buy

―

Reiterated

02/18/25

Unknown AnalystCantor Fitzgerald

Not Ranked

Cantor Fitzgerald

―

Buy

―

Reiterated

07/05/24

Cantor Fitzgerald reiterates Overweight Rating on Arcus Biosciences (RCUS)Cantor Fitzgerald analyst Alethia Young reiterated an Overweight rating on Arcus Biosciences (NYSE: RCUS).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arcus Biosciences

1 Month

xxx

Success Rate

6/12 ratings generated profit

Average Return

+2.26%

initiated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +2.26% per trade.

3 Months

xxx

Success Rate

9/20 ratings generated profit

Average Return

-5.88%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 45.00% of your transactions generating a profit, with an average return of -5.88% per trade.

1 Year

Robert DriscollWedbush

Success Rate

4/12 ratings generated profit

Average Return

-16.55%

initiated a buy rating last month

Copying Robert Driscoll's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -16.55% per trade.

2 Years

xxx

Success Rate

2/12 ratings generated profit

Average Return

-24.84%

initiated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 16.67% of your transactions generating a profit, with an average return of -24.84% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RCUS Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RCUS has received 17 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. RCUS average Analyst price target in the past 3 months is 25.29.

Each month's total comprises the sum of three months' worth of ratings.

RCUS Financial Forecast

RCUS Earnings Forecast

Next quarter’s earnings estimate for RCUS is -$1.13 with a range of -$1.38 to -$0.91. The previous quarter’s EPS was -$1.14. RCUS beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.97% of the time in the same period. In the last calendar year RCUS has Outperformed its overall industry.

RCUS Sales Forecast

Next quarter’s sales forecast for RCUS is $32.86M with a range of $20.00M to $65.00M. The previous quarter’s sales results were $28.00M. RCUS beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.48% of the time in the same period. In the last calendar year RCUS has Outperformed its overall industry.

RCUS Stock Forecast FAQ

What is RCUS’s average 12-month price target, according to analysts?

Based on analyst ratings, Arcus Biosciences Inc’s 12-month average price target is 25.29.

What is RCUS’s upside potential, based on the analysts’ average price target?

Arcus Biosciences Inc has 170.48% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RCUS a Buy, Sell or Hold?

Arcus Biosciences Inc has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

What is Arcus Biosciences Inc’s price target?

The average price target for Arcus Biosciences Inc is 25.29. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $46.00 ,the lowest forecast is $12.00. The average price target represents 170.48% Increase from the current price of $9.35.

What do analysts say about Arcus Biosciences Inc?

Arcus Biosciences Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of RCUS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Arcus Biosciences (RCUS) Stock Forecast & Price Target

RCUS Analyst Ratings

RCUS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Arcus Biosciences

RCUS Analyst Recommendation Trends

RCUS Financial Forecast

RCUS Earnings Forecast

RCUS Sales Forecast

RCUS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts